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Abstract: The pathophysiology of chronic obstructive pulmonary disease (COPD) includes 
persistent airflow limitation, altered gas exchange, and enhanced chronic inflammatory 
response. According to disease severity in individual patients, exacerbations and comorbidities 
frequently occur. The overall nocturnal and daily symptoms have a strong impact on patient 
quality of life and clinical outcomes. Bronchodilators, by targeting two important aspects of 
COPD pathophysiology, ie, bronchoconstriction and lung hyperinflation, are the mainstay of 
therapy for COPD. Aclidinium bromide in particular is an anticholinergic molecule, approved 
for maintenance bronchodilator treatment of stable COPD, that combines high antimuscarinic 
activity with strong kinetic selectivity for the M3 receptor subtype. Moreover, the elevated plasma 
clearance of aclidinium has been related to low systemic bioavailability and low incidence of 
anticholinergic adverse events, whereas the reduced residence time at M2 receptors provides 
good cardiovascular safety. Altogether, these characteristics result in a high safety and toler-
ability profile. This review aims to reappraise the contribution of symptoms and of the level of 
quality of life determinants on COPD severity and to evaluate how therapeutic strategies with 
aclidinium may positively impact on these specific determinants of disease severity.
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Introduction
Chronic obstructive pulmonary disease (COPD) is a common preventable and treatable 
disease, characterized by persistent airflow limitation that is not fully reversible and 
usually progressive. COPD may often be associated with extrapulmonary concomitant 
conditions, including cardiovascular and metabolic disease. The natural history of 
the disease is punctuated by recurrent episodes of worsening in symptoms and lung 
function termed “exacerbations”. Comorbidities and exacerbations contribute to the 
overall severity in individual patients. COPD is, among chronic conditions, one of the 
principal causes of years lived with disability and mortality.1
According to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) 
international guidelines, respiratory symptoms and the impact of symptoms on 
quality of life (QoL) are important determinants of the disease severity and of the 
treatment strategy.2
Long-acting muscarinic antagonists (LAMAs) are key to performing maintenance 
treatments in COPD patients. Aclidinium bromide was approved by the European 
Medicines Agency and the US Food and Drug Administration in 2012 for mainte-
nance bronchodilator treatment in stable adult patients with COPD.3 Aclidinium has 
high affinity for all five muscarinic receptors and a lower potential for anticholinergic 
adverse events.4
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This review aims to reappraise the contribution of 
symptoms and of the level of QoL determinants on COPD 
severity and to evaluate how therapeutic strategies with the 
LAMA aclidinium may positively impact on these specific 
determinants of disease severity.
Determinants of COPD severity: 
focus on symptoms and QoL
Symptoms in COPD
Cough, dyspnea, and sputum production are hallmarks of 
respiratory symptoms in COPD and may occur many years 
before airflow limitation. These symptoms occur across all 
levels of disease severity and show very weak correlations 
between the severity of lung function obstruction and the mag-
nitude of symptomatology. A noninterventional multicenter 
study, designed to better characterize COPD phenotypes in a 
large cohort of COPD patients, showed that airflow limitation 
measured as forced expiratory volume in 1 second reduction 
does not capture the heterogeneity of the disease.5
Indeed, airflow limitation was poorly, albeit significantly, 
associated with breathlessness. Moreover, there was a con-
siderable overlap between GOLD stages, with up to 40% 
of mild COPD patients experiencing moderate-to-severe 
dyspnea and up to approximately 25% of COPD patients 
with very severe airflow obstruction experiencing very mild 
or no dyspnea.5 These data clearly indicate that lung function 
measurement (which is essential for diagnosis and evalua-
tion of a COPD patient) cannot be regarded as a surrogate of 
symptom severity and that the symptoms (and in particular 
dyspnea) must be specifically evaluated. The presence and 
persistence of chronic symptoms negatively impact the 
clinical manifestation of COPD, irrespective of the severity of 
airflow limitation, and patients with symptomatic COPD (in 
particular with dyspnea) exhibit poorer long-term prognosis/
survival compared with asymptomatic patients.6
Several concomitant conditions can contribute to dyspnea 
in a COPD patient, including chronic heart failure, anemia, 
cachexia, malnutrition, etc. In this regard, one can speculate 
that the presence of dyspnea can reflect not only the severity 
of the airflow obstruction but also more generally the sever-
ity of a COPD patient. The GOLD international guidelines 
propose the Modified British Medical Research Council 
(mMRC) Dyspnea Scale as a simple grading system to assess 
a patient’s level of dyspnea/shortness of breath.7 Indeed, the 
mMRC correlates well with other measures of health status 
and predicts future mortality risk. The scale scores the dys-
pnea based on physical activity limitations ranging from 0 
“I only get breathless with strenuous exercise” to 4 “I am 
too breathless to leave the house or I am breathless when 
dressing”. Despite mMRC being a simple and quick tool 
that can be used in daily clinical activity, its main limitation 
is an inability to provide a comprehensive assessment of the 
multiple symptomatic effects of COPD.8
Symptom heterogeneity and variability 
in COPD
Chronic and daily variable symptoms are characteristics of the 
clinical manifestation of the disease. An observational mul-
ticenter European study evaluated the perception by COPD 
patients of respiratory symptoms over the day, the week, and 
the seasons. This study determined that more than 60% of 
patients with severe COPD reported respiratory symptoms 
with a worse perception in the morning.9 An internet-based 
questionnaire survey on more than 800 COPD patients from 
Europe and the USA, including 289 patients with severe 
COPD, also addressed the perception of COPD symptoms 
at different times in the day and night, assessing their impact 
on morning activities and on the daily routine of the patients. 
The study confirmed morning as the worst time of the day 
in 46% patients with severe COPD. Interestingly, nighttime 
was the second most difficult time of the day, as reported 
by 34% of severe COPD patients.10 Other more recent 
epidemiological data indicate that nocturnal symptoms and 
related sleep disturbances have a much higher prevalence, 
correlated with disease severity and exceeding 75% among 
patients with most severe COPD.11
To further evaluate the characteristics of nighttime 
symptoms in COPD, a prospective study assessed the poly-
somnographic and arterial oxygen saturation profiles along 
with other sleep parameters in a cohort of COPD patients 
with stable mild-to-moderate COPD, compared with matched 
controls with no airflow obstruction. The results of this study 
revealed that patients with COPD had an overall lower sleep 
efficiency, a lower total sleep time, and lower mean overnight 
oxygen saturation. Moreover, these patients were signifi-
cantly more likely to be reporting insomnia and difficulty 
in initiating and maintaining sleep, resulting in an increased 
score of overall psychiatric sleep disorders.12
Several causes and mechanisms have been claimed to 
explain the increased symptomatology of COPD patients 
during nighttime/sleep time, including age and obesity, 
therapy with certain drugs, disease-specific symptoms (ie, 
wheezing and cough), or comorbidities related to sleep 
disorders, including COPD-dependent psychological 
distress.13 Specific functional alterations occurring at nighttime 
can be responsible for altered respiratory symptomatology. In 
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particular, a study on nocturnal oxyhemoglobin desaturation 
has shown that the supine position impaired the functional 
residual capacity in COPD patients, with consequent increase 
of pulmonary hyperinflation.14 On the other hand, hypoxemia 
caused by altered lung function in COPD has been associated 
with interference with normal sleep architecture.15
The long-term consequences of nocturnal symptoms 
and altered sleep structure may have a severe impact 
on the outcome of COPD patients, because altered lung 
functions, onset or aggravation of cardiovascular comor-
bidities, increase of the frequency of exacerbations, and 
mental disturbances generally impair QoL and may finally 
increase the risk of death13 (Figure 1). In this regard, a ret-
rospective study examined nocturnal hyperinflation, one 
of the most common COPD symptoms associated with 
reduced sleep efficiency. Both polysomnography data and 
pulmonary function tests were performed, revealing a statisti-
cally significant association between increased severity of 
lung hyperinflation and worse sleep efficiency.16 Indeed, not 
only are nighttime/sleep time symptoms frequently present 
in COPD, but also even more importantly they are clinically 
relevant. An interesting epidemiological study revealed that 
the prevalence of nighttime symptoms, in particular dyspnea, 
is a significant predictor of poor prognosis in COPD, being 
associated with increased exacerbation rate and shorter sur-
vival.17 These data suggest that targeting the worsening of 
nighttime symptoms can be of clinical relevance in COPD 
patients. Nevertheless, nocturnal symptoms are often under-
estimated by physicians, while patients with COPD suffering 
nighttime symptoms do not always report these symptoms 
and the related sleep disturbances.13
Altogether, these data identify nighttime dyspnea and, 
more generally, chronic dyspnea as a valuable predictor of 
poor prognosis in COPD patients.17 According to the GOLD 
guidelines, the level of these symptoms (and in particular of 
dyspnea) contributes to the assessment of disease severity.8 
Moreover, monitoring of these symptoms guides the clinician 
in determining when the therapy needs to be modified and in 
identifying a relevant target for intervention.
QoL in COPD
QoL measures a complex array of patient-reported outcomes, 
including physical, psychological, and social components, 
which have particular relevance in a chronic disease like 
COPD. These range from symptoms (cough, sputum produc-
tion, shortness of breath or dyspnea, and wheezing attacks) 
to interference with daily work and social activity, even 
causing a nuisance with family or friends and embarrass-
ment in public.
The importance of measuring QoL relies not only on its 
ability to identify COPD features causing problems to the 
patients but also in a greater ability to discriminate among dif-
ferent levels of severity stages of COPD and to correlate with 
clinical measures of COPD more effectively than generic 
measures of health.18 It has been demonstrated that QoL has a 
strong impact on the long-term prognosis of COPD patients.17 
Moreover, a study on more than 300 patients showed that 
QoL was an independent risk factor for mortality in COPD.19 
Similar to symptoms, QoL also correlates weakly with lung 
function. A cohort of COPD patients from primary care set-
tings across seven countries in Europe was the subject of a 
cross-sectional, observational study on QoL, investigated 
by means of disease-specific and generic questionnaires. 
The results revealed that even patients with mild and moderate 
Figure 1 Diagrammatic representation of the different features of COPD and of 
their mutual relationships, converging toward impairment of QoL and increased 
risk of mortality.
Notes: The decline in lung function, accompanied by airflow limitation, causing 
hyperinflation and dyspnea, is correlated with the extent of airway inflammation 
and contributes to parenchymal damage, which causes abnormal gas transfer with 
the consequent hypoxemia and hypercapnia, leading to pulmonary hypertension. 
The abnormal inflammatory response to noxious particles and gases is dependent 
on airway chronic inflammation and correlates with several comorbidities. These 
alterations are at the basis of nocturnal and whole-day symptoms and of reduced 
physical activity. All symptoms and limitations determine a poor QoL that is 
associated with an enhanced mortality risk.
Abbreviation: QoL, quality of life.
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COPD experience high levels of respiratory symptoms and 
physical impairment.20 Similarly, the ECLIPSE cohort study 
showed that COPD patients with mild airflow obstruction 
can exhibit poor QoL.5 Therefore, impaired lung function 
cannot be considered a surrogate for poor QoL, which must 
be specifically measured in COPD patients.
The disease-specific St George Respiratory Questionnaire 
(SGRQ)21 allows the assessment of how disease activity 
impacts on a number of aspects of patient QoL and is widely 
accepted as a support of lung function measurements for the 
diagnosis of COPD.22 SGRQ is a self-administered question-
naire that was designed to measure the respiratory QoL and 
includes 50 items in three components: symptoms, activity, 
and impact on daily life. The scores range from 0 to 100 
(0 indicating no impairment in the QoL) and higher SGRQ 
scores represent worse QoL, with a score of 100 being the 
worst possible. The COPD Assessment Test was developed 
as a short, simple, unidimensional questionnaire based on 
eight items measuring the impairment of health status in 
COPD. The score system ranges from 0 to 40, closely cor-
related to that of SGRQ. The COPD Assessment Test is 
available as validated translations in 58 different languages, 
making it applicable worldwide.23
effects of symptoms on QoL
Several aspects can affect QoL. In particular, it has been 
shown that the presence of symptoms is an important deter-
minant of poor QoL in COPD patients. A recent observational 
study conducted in 85 clinical practice centers of eight 
European countries evaluated the symptom profile of more 
than 700 patients with COPD throughout the whole 24-hour 
day. Interestingly, the study showed a significant relationship 
between nighttime, early morning, and daytime symptoms, 
and that the presence of symptoms (in each period) was 
associated with worse patient-reported outcomes, including 
poor QoL.24 Likewise, a large study performed on more than 
2,800 patients from five European countries revealed that 
patients with nighttime symptoms scored a significantly lower 
QoL compared with patients without nocturnal symptoms.11 
Overall, these data pointed to the interdependence between 
worsening of symptoms and decline of QoL. The relief 
of chronic symptoms is part of the effective management 
of COPD with the goal of improving the QoL of patients. 
Long-term treatment with long-acting bronchodilators was 
successful in achieving these goals in COPD.25
Bronchodilator therapy
Bronchoconstriction and lung hyperinflation are impor-
tant determinants of the symptoms related to COPD. 
The evidence elucidating the importance not only of 
bronchodilation but also of pulmonary desufflation are 
strong and crucial for a better understanding of the effect 
of bronchodilators on respiratory clinical parameters such 
as dyspnea.26,27
A LAMA, alone or in combination with a long-acting 
β2-adrenergic agonist (LABA) and inhaled corticoster-
oids, is the most commonly used agents in the treatment of 
COPD. These combination treatments are recommended by 
the GOLD for the management of COPD patients as single 
agents (LAMA or LABA) or in combination, according to 
the stage of the disease, the patient response, and the risk 
of exacerbations.8 Long-acting bronchodilators have been 
established as standard treatment for COPD patients. The 
formulation of these agents, designed to be administered 
by inhalation, offers an optimized delivery to the targeted 
site and minimizes systemic bioavailability, thus reducing 
adverse effects. Aclidinium bromide, in particular, combines 
high selectivity for M3 muscarinic receptors, long duration 
of action, and rapid clearance in plasma. This long-acting 
inhaled bronchodilator is effective in reducing exacerbations 
and related hospitalizations and in improving symptoms and 
health status in COPD.28–31
Inhaled aclidinium bromide
Aclidinium bromide, containing a quaternized (3R)-quinu-
clidinol ester, with the chemical formula 3R-(2-hydroxy- 
2,2-dithiophen-2-yl-acetoxy)-1-(3-phenoxy-propyl)-1-
azonia-bicyclo[2.2.2]octane bromide, is an inhaled LAMA 
which, as noted previously, was approved by the US Food 
and Drug Administration and the European Medicines 
Agency in 2012 for use in moderate-to-severe stable COPD 
patients. According to all preliminary clinical and registra-
tion studies, aclidinium bromide is generally well tolerated 
in patients with COPD, with a low incidence of antimus-
carinic (anticholinergic) adverse effects and with safety 
profiles similar to placebo.28,29 Several adverse effects, such 
as tachycardia and digestive tract disturbances, have been 
associated with the administration of muscarinic antagonists, 
and many efforts have been made to design formulations with 
reduced bioavailability. Aclidinium bromide, in contrast to 
tiotropium and ipratropium, displays an increased plasma 
clearance, with a lower potential for systemic adverse events. 
Moreover, aclidinium bromide has a long residence half-life 
at M3 receptors (located on airway smooth muscle) and a 
reduced residence half-life at M2 receptors (mainly located 
in the heart), resulting in selective antagonism to the M3 
receptors.4 A recent randomized, double-blind, crossover 
study demonstrated that even in severe and very severe 
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COPD patients, a rapid and important desufflation, along 
with the improvement in lung ventilation inhomogeneity, 
is promoted by aclidinium.32 These results are of particular 
relevance in view of the main pathophysiological role played 
by hyperinflation and airflow limitation in inducing dyspnea 
and reducing QoL in patients with COPD.
Since inhalation is the optimal route of administration 
of bronchodilators, the inhaler device is as relevant as the 
drug(s) in the management of COPD.33 As recommended by 
the consensus statement of the European Respiratory Society 
(ERS), the choice of the aerosol delivery device should be 
based on the patient’s ability, inspiratory flow levels, and 
other clinical conditions.34 A recent survey on a representative 
sample of the Italian elderly patient population showed that 
the large majority of these patients considered the multidose 
breath-actuated dry powder inhaler device, Genuair®, well 
accepted and easy to use, irrespective of the presence of 
age-related difficulties.35
effects of aclidinium on symptoms and QoL
Two Phase III studies, the ATTAIN 24-week, double-
blind trial (NCT01001494) on more than 800 patients and 
the ACCORD-I 12-week, double-blind, multicenter trial 
(NCT00891462) on more than 500 patients, assessed the 
efficacy of 6 weeks treatment with aclidinium bromide 
versus placebo in patients with COPD28,29 (Figures 2 and 3). 
The results of both trials showed that inhaled aclidinium 
bromide significantly improved bronchodilation, health sta-
tus, and dyspnea versus placebo.28,29 The ACCORD-I study 
found a significant reduction in the frequency and severity 
of nocturnal symptoms compared with placebo at Week 12 
in patients treated with both doses of aclidinium.29
Pharmacological trials on the comparison between 
LAMAs on relevant clinical outcomes of COPD are very 
important to help and support the treatment decision process 
of the physicians. A recent systematic review and network 
meta-analysis evaluated the comparative efficacy of LAMA 
Figure 2 Changes from baseline SGRQ total score of ACCORD study29 and ATTAIN study.28
Notes: The results of ATTAIN study are related to the evaluation after 12 and 24 weeks of therapy. Data are reported as mean values.
Abbreviations: SGRQ, St George Respiratory Questionnaire; w, week; MCID, minimal clinically important difference.
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monotherapies in COPD.36 While, two trials included a head-
to-head comparison between aclidinium and tiotropium in the 
study design. A Phase IIa randomized, double-blind, double-
dummy, crossover trial (NCT00868231) compared inhaled 
aclidinium bromide 400 μg bid (twice daily) with tiotropium 
18 μg qd (once daily) and with placebo for 15 days, with a 
9- to 15-day washout between treatment periods. Results 
derived from symptoms diaries revealed significant 
improvements from baseline in nighttime symptoms with 
bid aclidinium versus placebo, which were not observed with 
daily tiotropium.37 Reductions in COPD symptom score were 
consistently greater with aclidinium than with tiotropium, but 
these differences did not reach statistical significance.37
A randomized, double-blind, Phase IIIb study 
(NCT01462929) compared the bronchodilation efficacy 
of aclidinium bromide vs tiotropium and vs placebo over 
a period of 24 hours in patients with moderate-to-severe 
COPD.37 Pulmonary function and symptoms were examined 
in more than 400 patients. The results indicated that aclidin-
ium 400 μg bid ensured a 24-hour effective bronchodilation 
and provided a significant improvement of early morning 
activities and greater improvement of COPD symptoms, 
compared with tiotropium.38
Other LAMAs are available for long-term inhaled 
treatment of COPD, including glycopyrronium and umecli-
dinium. A significant improvement in QoL and symptom 
scores compared with placebo have been shown also for 
glycopyrronium39 and umeclidinium,40 but no direct com-
parison with aclidinium is available. Thus, any conclusion 
on the relative effectiveness of these molecules on the tested 
clinical outcomes can be biased by methodological study 
concerns including different severity of the patients recruited, 
different sample size, and different duration of the studies 
and outcomes.
A relevant point in evaluating aclidinium therapy is that 
the improvement in clinical outcomes (symptom control and 
improvement of QoL) is spread from moderate-to-severe 
COPD patients, with remarkably low rates and severity of 
adverse events (Table 1).
Conclusion
In COPD patients, the presence of chronic respiratory 
symptoms is a key determinant of the severity of the disease. 
The symptoms associated with COPD, beyond affecting 
functional capacity and physical activity of the patients, 
have a strong impact on QoL, which in turn is also a deter-
minant of COPD severity.9 Even more importantly, the 
presence/persistence of respiratory symptoms resulted in a T
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significantly increased risk of long-term mortality during the 
follow-up period of 11 years in a prospective study on the 
large Atherosclerosis Risk in Communities cohort in USA.41 
In particular, severe dyspnea in COPD patients was identi-
fied as a risk factor for mortality, which normalized upon 
remission of the symptom, by a large longitudinal Dutch 
study with a follow-up of over 40 years.42
Staging of COPD severity based on pulmonary func-
tions is strongly correlated with clinical outcomes of COPD. 
However, measures of QoL are able to capture more broad 
aspects and complementary information to lung function data 
in assessing disease status and outcome.18 Indeed, QoL was 
found to be significantly impaired in COPD patients across 
all severity grades, even in those with milder disease, with 
little difference between GOLD stages and wide variation 
within each GOLD stage.20
Moreover, symptoms and QoL should be considered 
independently in the assessment and monitoring of COPD 
patients in primary care. In particular, nighttime symptoms 
are of relevance because of the strong impact on daily 
activity, and also because of the prognostic value.17 Clinicians 
and general practitioners should not neglect nighttime symp-
toms during their clinical interviews and should consider this 
aspect as a specific target for therapy.
Long-acting bronchodilators (LABAs and LAMAs) 
are the mainstay of therapy for patients with moderate and 
severe COPD. Aclidinium bromide, with high antimuscarinic 
activity and a favorable safety profile, has demonstrated 
efficacy in controlling COPD symptoms over the 24-hour day 
period, including nocturnal symptoms, with a relevant impact 
on QoL and prognosis, irrespective of disease severity.4,43 
In conclusion, the favorable benefit-to-risk ratio in the clinical 
setting indicates that aclidinium has potential as a valuable 
treatment option for patients with COPD.
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